Akèy › Melanom Uveal › Tennessee
Etid klinik pou Melanom Uveal nan Tennessee
6 etid pou Melanom Uveal ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
- Sarah Cannon Research Institute (SCRI), Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07804186A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
- Sarah Cannon Research Institute, Nashville
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Jun 15, 2026 · NCT06940739Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 8, 2026 · NCT03947385Neoadjuvant Darovasertib in Primary Uveal Melanoma
- SCRI Oncology Partners, Nashville
- Vanderbilt Eye Institute, Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- The West Clinic, PLLC dba West Cancer Center, Germantown
- University of Tennessee Medical Center, Knoxville
- Sarah Cannon Research Institute, Nashville
- ak 1 plis
Ap rekriteFaz 2/3
Tout laj · Tout sèks · Mizajou Apr 2, 2026 · NCT06581406Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
- SCRI Oncology Partners, Nashville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 28, 2025 · NCT07136181Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.